Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2011) 27 OC2.8

BSPED2011 Oral Communications Oral Communications 2 (Quick Fire) (8 abstracts)

Novel SOX2 mutation: from clinical phenotype to identification of new molecular mechanisms of SOX2 action and interactions

Kyriaki S Alatzoglou 1 , Cynthia L Andoniadou 2 , Daniel Kelberman 3 , Hyoong-Goo Kim 4 , Jennifer Pedersen-White 4 , Lawrence Layman 4 , Juan Pedro Martinez-Barbera 2 & Mehul T Dattani 1


1Developmental Endocrinology Research Group, UCL Institute of Child Health, London, UK; 2Neural Development Unit, UCL Institute of Child Health, London, UK; 3Ulverscroft Vision Research Group, Developmental Biology Unit, UCL Institute of Child Health, London, UK; 4Section of Endocrinology, Diabetes and Metabolism, The Medical College of Georgia, Augusta, Georgia, USA.


Background: SOX2 is an early developmental transcription factor implicated in pituitary development. It consists of a N-terminal domain, a high mobility group (HMG)-DNA binding domain and a carboxyl-terminal domain. Heterozygous SOX2 mutations have been described in patients with a severe ocular phenotype and hypogonadotrophic hypogonadism (HH) with/without associated abnormalities. In vitro SOX2 interacts with β-catenin, a member of the Wnt signalling pathway, and represses β-catenin mediated target activation via the carboxyl-terminus. We now report a novel SOX2 mutation in the HMG domain revealing a distinct mechanism of action.

Case presentation: A female patient first presented at the age of 21 years with primary amenorrhoea (breast stage 2). She had bilateral congenital anophthalmia, developmental delay and HH (FSH 1.0 IU/l, LH 0.6 IU/l, oestradiol <15 pg/ml) with thinning of the corpus callosum on MRI.

Results: Genetic analysis revealed heterozygosity for a novel SOX2 mutation (c.G261T, p.K87N) in the HMG domain. The mutant protein had comparable transactivation to the wild type (WT) SOX2 (P>0.5) and, unlike previous HMG domain mutations, retained its ability to bind to a consensus DNA probe on electrophoretic mobility shift assay (EMSA). Immunostaining confirmed nuclear localisation. However, co-transfection of p.K87N SOX2 with a constitutively active form of human β-catenin (S33Y) in the TOPFLASH reporter assay failed to repress β-catenin mediated activation (P<0.001), in contrast to WT SOX2. This may result from altered direct interaction with β-catenin rather than binding to TCF/LEF sites, as we demonstrate that neither WT nor p.K87N SOX2 bind to a TCF/LEF consensus probe on EMSA.

Conclusion: We report a novel SOX2 mutation in the HMG domain that, unexpectedly, fails to repress β-catenin mediated activation suggesting that the HMG domain is critical for the interaction with β-catenin. We report, for the first time to our knowledge, that clinical phenotypes may result from altered interaction between SOX2 and β-catenin.

Volume 27

39th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.